GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genomic Valley Biotech Ltd (BOM:539206) » Definitions » Equity-to-Asset

Genomic Valley Biotech (BOM:539206) Equity-to-Asset : 0.00 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Genomic Valley Biotech Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Genomic Valley Biotech's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₹0.00 Mil. Genomic Valley Biotech's Total Assets for the quarter that ended in Dec. 2023 was ₹0.00 Mil.

The historical rank and industry rank for Genomic Valley Biotech's Equity-to-Asset or its related term are showing as below:

BOM:539206' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.53   Med: 0.73   Max: 0.83
Current: 0.53

During the past 9 years, the highest Equity to Asset Ratio of Genomic Valley Biotech was 0.83. The lowest was 0.53. And the median was 0.73.

BOM:539206's Equity-to-Asset is ranked worse than
61.69% of 1566 companies
in the Biotechnology industry
Industry Median: 0.665 vs BOM:539206: 0.53

Genomic Valley Biotech Equity-to-Asset Historical Data

The historical data trend for Genomic Valley Biotech's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomic Valley Biotech Equity-to-Asset Chart

Genomic Valley Biotech Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only 0.66 0.63 0.59 0.76 0.80

Genomic Valley Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.80 - 0.53 -

Competitive Comparison of Genomic Valley Biotech's Equity-to-Asset

For the Biotechnology subindustry, Genomic Valley Biotech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomic Valley Biotech's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genomic Valley Biotech's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Genomic Valley Biotech's Equity-to-Asset falls into.



Genomic Valley Biotech Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Genomic Valley Biotech's Equity to Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Equity to Asset (A: Mar. 2023 )=Total Stockholders Equity/Total Assets
=35.269/44.204
=0.80

Genomic Valley Biotech's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=0/0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genomic Valley Biotech  (BOM:539206) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Genomic Valley Biotech Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Genomic Valley Biotech's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Genomic Valley Biotech (BOM:539206) Business Description

Traded in Other Exchanges
N/A
Address
4 K.M. Stone, Berri Charra Road, P.O. Tandaheri, Tehsil-Bahadurgarh, Village Kherka Musalman, Jhajjar, HR, IND, 124507
Genomic Valley Biotech Ltd is an India-based company engaged in providing diagnostic services and related business services. It undertakes commercial production of plant tissue cultured plants of different species to feed the genetically improved plant market nationally as well as internationally. The group conducts research in the field of agriculture, plant tissue culture, medical biotechnology, SERI biotechnology, stem cell, food biotechnology, Drone technology, Poly House Construction, and others. It generates revenue from the sale of services.

Genomic Valley Biotech (BOM:539206) Headlines

No Headlines